Authors : Aguirre-Ghiso JA; Division of Hematology and Oncology, Department of Medicine, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York, USA. ; Bragado P

Subjects: Neoplasm Metastasis/Neoplasm Metastasis/Neoplasm Metastasis/*drug therapy ; Neoplasm, Residual/Neoplasm, Residual/Neoplasm, Residual/*drug therapy ; Neoplasms/Neoplasms/Neoplasms/*drug therapy

Source: Nature medicine [Nat Med] 2013 Mar; Vol. 19 (3), pp. 276-7.Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma

Authors : Chamutal Bornstein; Irit Avivi; Moshe E. Gatt ...

Subjects: Adult; Aged, 80 and over; Male

Source: Dadun. Depósito Académico Digital de la Universidad de NavarraUniversidad de NavarrainstnameNature Medicine

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer

Authors : Khyati N. Shah; Roma Bhatt; Julia Rotow

Subjects: Biomedical and clinical sciences; Lung Neoplasms; Neoplasm, Residual

Source: Nat MedNature Medicine, vol 25, iss 1

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

A framework for understanding and targeting residual disease in oncogene-driven solid cancers

Authors : Bivona, Trever G; Doebele, Robert C

Subjects: 0301 basic medicine; Biomedical and clinical sciences; Neoplasm, Residual

Source: Nature Medicine, vol 22, iss 5

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence

Authors : Peter Selby; Jose S. Pulido; Oliver Donnelly

Subjects: Neoplasm, Residual; Skin Neoplasms; T-Lymphocytes

Source: Nature Medicine. 19:1625-1631

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia

Authors : Ikuta Tanaka; Tsutomu Sato; Naofumi Takemoto

Subjects: 0301 basic medicine; Antimetabolites, Antineoplastic; Leukemia

Source: Nature Medicine. 9:1158-1165

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Metastasis awakening: the challenges of targeting minimal residual cancer.

Authors : Polzer B; Fraunhofer-Institut für Toxikologie und Experimentelle Medizin, Project Group Personalized Tumor Therapy, Regensburg, Germany.; Klein CA

Subjects: Drug Resistance, Neoplasm*; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use ; Neoplasm Metastasis/Neoplasm Metastasis/Neoplasm Metastasis/*pathology

Source: Nature medicine [Nat Med] 2013 Mar; Vol. 19 (3), pp. 274-5.Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer

Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response

Metastasis awakening: targeting dormant cancer.

Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer

A framework for understanding and targeting residual disease in oncogene-driven solid cancers

Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence

Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia

Metastasis awakening: the challenges of targeting minimal residual cancer.

اتصل بنا

اتبع